Data completeness
4/8 — Partial
METAXALONE (metaxalone) by Pfizer is rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions has not been established, but may be due to general cns depression. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metaxalone is an oral muscle relaxant tablet approved by the FDA in 2015 for acute, painful musculoskeletal conditions as an adjunct to rest and physical therapy. The mechanism of action is not fully established but is presumed to involve general CNS depression rather than direct action on muscle tissue. It is indicated for symptomatic relief of discomfort in patients with acute musculoskeletal injuries.
$0.304MPart D
Peak13.2 years to LOEPeak lifecycle status with minimal Part D spending and claims suggests a niche, stable-volume product with limited commercial growth potential and likely small-to-mid sized brand team.
Mechanism of Action
rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions has not been established, but may be due to general CNS depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate,…
Pharmacologic Class:
Muscle Relaxant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Metaxalone currently shows zero linked job postings, reflecting its niche market position and stable, low-growth commercial profile. Professionals joining this product would focus on maintenance-mode brand management, managed care, and regulatory compliance rather than growth-oriented commercial development.
Company
Worked on METAXALONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.